Last reviewed · How we verify
DHP107
DHP107 is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
DHP107 is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.
At a glance
| Generic name | DHP107 |
|---|---|
| Also known as | Liporaxel®, Oral Paclitaxel |
| Sponsor | Daehwa Pharmaceutical Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting SGLT2, DHP107 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased glucose levels in the blood. This mechanism is thought to contribute to its therapeutic effects in treating diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer (NA)
- Phase 3 Study to Compare Efficacy and Safety of DHP107 vs. Taxol® in Patients With Metastatic or Recurrent Gastric Cancer (PHASE3)
- Food Effect on Pharmacokinetics and Safety of DHP107 (Liporaxel®) FEEL Study (PHASE1)
- Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer (PHASE2)
- A Study DHP107, a Novel Oral Paclitaxel Formulation, in Patients With Advanced Solid Tumours or Gastric Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |